Evidence map›Paper›PMID 35644734›Full record

ArticleJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy2022

Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan.

Nobumasa Okumura, Shinya Tsuzuki, Sho Saito, Shin-Ichiro Hattori, Junko S Takeuchi, Tomoya Saito, Mugen Ujiie, Masayuki Hojo, Noriko Iwamoto, Wataru Sugiura and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nobumasa OkumuraDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Shinya TsuzukiDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Sho SaitoDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: ssaito@hosp.ncgm.go.jp.
Shin-Ichiro HattoriDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Junko S TakeuchiCenter for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Tomoya SaitoCenter for Emergency Preparedness and Response, National Institute of Infectious Diseases, Tokyo, Japan.
Mugen UjiieDepartment of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.
Masayuki HojoDepartment of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.
Noriko IwamotoDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Wataru SugiuraCenter for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
Hiroaki MitsuyaDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Omicron variant of severe acute respiratory syndrome coronavirus 2 has multiple amino acid mutations in its spike proteins, which may allow it to evade immunity elicited by vaccination. We examined the neutralising activity and S1-IgG titres in patients with breakthrough infections caused by the Omicron variant after two doses of vaccination. We found that neutralising activity was significantly lower for the Omicron variant than for the Wuhan strain. Two doses of vaccination might not induce sufficient neutralising activity for the Omicron variant.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralHumansJapanAntibodies, ViralAntibody titreBreakthrough infectionCoronavirus disease 2019 (COVID-19)Neutralising activityOmicron

Identifiers

PMID35644734
PMCPMC9023325

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.